Supplementary Figure S1. Tumor volume in CD49d+ and CD49d− CLL during acalabrutinib treatment
No takes yet. Share an insight, caveat, or question.
Alsadhan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: